FDA Sanofi - Search News

Pfizer names former FDA director

Pfizer names former FDA director as chief medical officer

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing back an industry veteran to lead its regulatory and drug safety operations.

BioPharma Dive · 16h

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion, who’s leaving the drugmaker.

Bloomberg on MSN · 17h

Pfizer Names Former FDA Drug Chief as Top Doctor

Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.

Seeking Alpha on MSN · 16h

Pfizer taps former FDA drug chief as chief medical officer

Pfizer (NYSE:PFE) has tapped Patrizia Cavazzoni, the former head of drug regulation at the FDA, as its new chief medical officer. Cavazzoni was most recently director of the Center for Drug Evaluation and Research (CDER) at the U.

GlobalData on MSN6d

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Sanofi treatment of autoimmune hemolytic anemia granted orphan status

The FDA granted orphan designation to Sanofi ( SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on TheFly – ...

Pharm Exec7d

FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...

BioSpace7d

Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Nasdaq7d

Regeneron and Sanofi Announce FDA Priority Review for Dupixent® as Potential First Targeted Treatment for Bullous Pemphigoid

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has ...

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

PMLiVE5d

Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...

Notable healthcare headlines for the week: UnitedHealth, Moderna, Sanofi in focus

Health sector stocks fluctuate amid DOJ probe into UnitedHealth (UNH), Gilead upgrade for HIV treatments, and Moderna's focus on non-COVID approvals.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results